Date | Price Target | Rating | Analyst |
---|---|---|---|
5/22/2024 | $85.00 | Buy → Neutral | Citigroup |
2/8/2024 | $80.00 | Sector Outperform | Scotiabank |
2/2/2024 | $65.00 | Buy → Hold | Stifel |
12/7/2023 | $80.00 | Buy | UBS |
8/28/2023 | Outperform | William Blair | |
1/10/2023 | $90.00 | Underweight → Equal Weight | Wells Fargo |
12/14/2022 | $100.00 | Buy | Deutsche Bank |
12/12/2022 | $81.25 → $100.00 | Neutral → Buy | Citigroup |
4 analysts have shared their evaluations of Bio-Techne (NASDAQ:TECH) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 1 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.75, with a high estimate of $95.00 and a low estimate of $81.00. This current average ref
Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and announces $85 price target.
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
4 - BIO-TECHNE Corp (0000842023) (Issuer)
ST. PAUL, Minn., Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ:TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex® Grant. ImmunoScape's $250,000 G-Rex® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell therapy. "We are thankful for ScaleReady's G-Rex Grant Program and are grateful to receive an award that will substantially defray the time and cost of bringing our novel therapy into the clinic," said Dr. Tania Ribeiro, Senior Director and Head of CMC. "We are proud to award Immu
MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate culture and provide the foundation for our approach to continuously improving our corporate sustainability. The updated CSR is available in the Corporate and Social Responsibility section of Bio-
PHILADELPHIA, Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. The G-Rex Grant Program offers recipients significant support
MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s
MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D
MINNEAPOLIS, Jan. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Shane Bohnen has been appointed Senior Vice President, General Counsel effective March 3, 2023. Mr. Bohnen succeeds Brenda Furlow, who will be retiring from the Company after serving as Executive Vice President and General Counsel for the past nine years. Brenda has been and will continue to provide transition support until her March 3, 2023, retirement and will serve in a consulting capacity for special projects going forward. Mr. Bohnen has over 20 years of experience as a senior legal advisor, including serving as Bio-Techne's Associate General Counsel since 2019. During his tenure at Bio-T
DEFA14A - BIO-TECHNE Corp (0000842023) (Filer)
DEF 14A - BIO-TECHNE Corp (0000842023) (Filer)
10-K - BIO-TECHNE Corp (0000842023) (Filer)
Citigroup downgraded Bio-Techne from Buy to Neutral and set a new price target of $85.00
Scotiabank initiated coverage of Bio-Techne with a rating of Sector Outperform and set a new price target of $80.00
Stifel downgraded Bio-Techne from Buy to Hold and set a new price target of $65.00
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth quarter ending June 30, 2024. Fourth Quarter FY2024 Highlights Fourth quarter organic revenue increased by 1% (2% reported) to $306.1 million. Full year organic revenue increased 1% (2% reported) to $1.2 billion.GAAP earnings per share (EPS) was $0.25 versus $0.47 one year ago. Delivered adjusted EPS of $0.49 compared to $0.55 one year ago. Full year GAAP EPS was $1.05 versus $1.76 one year ago. Full year adjusted EPS was $1.77 versus $1.99 one year ago.Strong commercial execution in Diagnostics & Genomics led to 9% organic segment growth (15% reported) in the fo
MINNEAPOLIS, Aug. 7, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2024. The quarterly dividend will be payable August 30, 2024, to all common shareholders of record on August 19, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific d
MINNEAPOLIS, July 15, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. CDT to review fourth quarter and fiscal 2024 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CDT Date: August 7, 2024 Dial-in: 1-800-343-4136 or 1-203-518-9843 (for international callers) Conference ID: BioTechne Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested